Search clinical trials for: vedolizumab

Total 239 results

Universita degli Studi di Genova

Withdrawn

Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF

Crohn Disease
Takeda

Withdrawn

Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease

Crohn's Disease | Ulcerative Colitis
Takeda

Completed

Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration

Healthy

United Kingdom
Ced Service GmbH

Recruiting

Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany (VEDOibdI)

Inflammatory Bowel Diseases | Treatment

Germany
Takeda

Completed

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

Crohn's Disease

Belgium, Israel, Korea, Republic of, Netherlands, Australia, Denmark, Russian Federation, Hungary, Serbia, Bulgaria, Canada, Germany, Italy, Poland, Slovakia, Czechia, Mexico, Romania, Brazil, Estonia, United States, Bosnia and Herzegovina and more
Mayo Clinic

Withdrawn

Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.

Ulcerative Colitis | Dietary Modification

United States
Takeda

Active, not recruiting

A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

Crohn's Disease | Colitis, Ulcerative

United States, Belgium, Israel, Spain, Korea, Republic of, Taiwan, Netherlands, Australia, Denmark, Hungary, Italy, Russian Federation, Brazil, Croatia, Germany, Serbia, Bulgaria, Canada, Poland, Slovakia, Ukraine, Czechia, Argentina, Turke... and more
Takeda

Completed

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants

Healthy Volunteers

United States
Groupe d'Etude Therapeutique des Affections Inflammatoires...
Takeda

Recruiting

VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER) (DOPER)

Inflammatory Bowel Diseases

France
Geert D'Haens
Takeda

Completed

A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOVE-CD)

Crohn Disease

Belgium, Netherlands, Hungary
Takeda

Recruiting

A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Crohn's Disease

China
Takeda

Completed

A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease

Crohn Disease | Ulcerative Colitis

India
Millennium Pharmaceuticals, Inc.

Completed

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

Hematopoietic Stem Cells

United States, Spain, Taiwan, Australia, Canada, Singapore, Korea, Republic of, Mexico, Switzerland, Japan, Germany, Norway, Israel, Russian Federation, Hungary, United Kingdom, Italy, Romania, Brazil, France, Austria, Belgium, Port... and more
National Institute of Allergy and Infectious Diseases...

Completed

Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption

HIV

United States
Takeda

Not yet recruiting

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Crohn's Disease | Ulcerative Colitis
Takeda

Completed

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis (ENTERPRET)

Colitis, Ulcerative

United States, Canada
Takeda

Completed

Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis

Ulcerative Colitis

Japan
Takeda

Completed

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants

Healthy Volunteers

United States
Geert D'Haens
Takeda

Completed

An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis (LOVE-UC)

Colitis, Ulcerative

Netherlands, Belgium, Hungary
Takeda

Recruiting

Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis

China
Takeda

Completed

Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease

Crohn's Disease

Japan
Takeda

Completed

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

Colitis, Ulcerative

United States, Korea, Republic of, Netherlands, Australia, Denmark, Russian Federation, Spain, Croatia, Israel, Serbia, Bulgaria, Canada, Italy, Poland, Ukraine, Hungary, Belgium, Czechia, Turkey, Germany, Japan, Estonia, Mexico, Romania and more
Takeda

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Crohn's Disease (CD)

United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
University Medical Center Groningen

Completed

Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients (VISION)

Crohn Disease | Colitis, Ulcerative

Netherlands
Millennium Pharmaceuticals, Inc.

Completed

Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Crohn's Disease | Ulcerative Colitis

Canada
Washington University School of Medicine

Active, not recruiting

Defining Predictors of RT Response to Vedolizumab in IBD

Crohn Disease of Small Intestine

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease (GEMINI II)

Crohn's Disease

United States, Canada, Puerto Rico
Takeda

Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's Disease | Ulcerative Colitis

Belgium, Australia, Israel, United States, Hungary, Korea, Republic of, China, Canada, Croatia, Italy, Poland, Slovakia, United Kingdom, Japan, Greece
Takeda

Completed

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

Healthy Volunteers

United States
Hospitales Universitarios Virgen del Rocío
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Unknown

Vedolizumab Treatment in HIV-Infected Subjects Without Previous Antiretroviral Therapy

HIV Infections

Spain
Takeda

Recruiting

Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]

Crohn's Disease

Japan
Takeda

Completed

Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.

Crohn's Disease

China
Ottawa Hospital Research Institute
CHEO Research Institute; Nebraska Centre for Substance Abuse Research

Recruiting

Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection (HAVARTI)

HIV-infection/AIDS

Canada
Millennium Pharmaceuticals, Inc.

Completed

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease (GEMINI III)

Crohn's Disease

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis (GEMINI I)

Ulcerative Colitis

United States, Canada, Puerto Rico
GlaxoSmithKline

Completed

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma (DREAM)

Asthma

United States, Argentina, Australia, Germany, Poland, Romania, Russian Federation, Ukraine, Canada, Chile, France, Korea, Republic of, United Kingdom
Alimentiv Inc.
Takeda

Not yet recruiting

VOICE-Early Response to Vedolizumab and Ustekinumab in Participants With Crohn's Disease: A Prospective Observational Study (VOICE)

Crohn's Disease
Academisch Medisch Centrum - Universiteit van Amsterdam...
GlaxoSmithKline; The Netherlands Asthma Foundation

Unknown

Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations (MATERIAL)

Asthma | Viral Infection

Netherlands
Takeda

Completed

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Colitis, Ulcerative

United States, Belgium, Israel, Spain, Korea, Republic of, Taiwan, Netherlands, Australia, Denmark, Hungary, Russian Federation, Italy, Croatia, Hong Kong, Germany, Portugal, Serbia, Canada, Poland, Bulgaria, Ukraine, Colombia, Turkey, Czech... and more
Nantes University Hospital
Institut National de la Santé Et de la Recherche Médicale, France; Takeda; Mauna...

Terminated

Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT) (DETECT)

ULCERATIVE COLITIS

France
Maruho Co., Ltd.

Active, not recruiting

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

Systemic Sclerosis

Japan
King's College Hospital NHS Trust

Active, not recruiting

Study for Children & Adolescent With Severe Asthma With an Eosinophilic Phenotype Treated With Mepolizumab (CASAM)

Asthma in Children

United Kingdom
University Hospital, Montpellier

Completed

Nation-wide Health Resource Consumption and Costs Associated With Mepolizumab (Resala)

Asthma

France
GlaxoSmithKline

No longer available

This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic

Hypereosinophilic Syndrome
GlaxoSmithKline

Completed

A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622

Hypereosinophilic Syndrome

United States, Poland, Spain, France, Belgium, Germany, Argentina, Russian Federation, Mexico, Italy, Brazil, United Kingdom, Romania
University Hospital, Grenoble

Completed

Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma (Mepolizumab)

Asthma; Eosinophilic

France
GlaxoSmithKline

Completed

An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients

Oesophagitis, Eosinophilic

Switzerland
Fondazione Policlinico Universitario Agostino Gemelli...

Not yet recruiting

Mepolizumab in the Treatment of Patients With Severe Uncontrolled CRSwNP: a Multicentric Real Life Observational Study (MEPOREAL)

Chronic Rhinosinusitis With Nasal Polyps

Italy
University Hospital Southampton NHS Foundation...
GlaxoSmithKline

Not yet recruiting

Evaluation of Volatile Organic Compounds in Mepolizumab Therapy (EVOC4M)

Asthma; Eosinophilic

United Kingdom

Search clinical trials for: vedolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations